Advice
In the absence of a submission from the holder of the marketing authorisation:
pasireotide (as pamoate) (Signifor ®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- pasireotide (as pamoate) (Signifor)
- SMC ID:
- 1311/18
- Indication:
- Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 February 2018